We previously reported that Frizzled homologue 10 (FZD10), a member of the Wnt signal receptor family, was highly and specifically upregulated in synovial sarcoma and played critical roles in its cell survival and growth. We here report a possible molecular mechanism of the FZD10 signaling in synovial sarcoma cells. We found a significant enhancement of phosphorylation of the Dishevelled (Dvl)2/Dvl3 complex as well as activation of the Rac1-JNK cascade in synovial sarcoma cells in which FZD10 was overexpressed. Activation of the FZD10-Dvls-Rac1 pathway induced lamellipodia formation and enhanced anchorage-independent cell growth cells. FZD10 overexpression also caused the destruction of the actin cytoskeleton structure, probably through the downregulation of the RhoA activity. Our results have strongly implied that FZD10 transactivation causes the activation of the non-canonical Dvl-Rac1-JNK pathway and plays critical roles in the development/progression of synovial sarcomas.
Introduction
Synovial sarcoma accounts for 5-10% of all soft tissue sarcomas and its onset age is as young as 10-20 years (Weiss and Goldblum, 2001 ). Although it is called as 'synovial' sarcoma, it occurs in the head, neck, trunk, heart, lung, esophagus, bone marrow, larynx, kidney and prostate where no synovial tissue is present (Habu et al., 1998; Hiraga et al., 1999; Coindre et al., 2003; McGilbray and Schulz, 2003; Ochi et al., 2004; Szuhai et al., 2004; Williams et al., 2004; Hosono et al., 2005; Shannon et al., 2005) . Hence, efforts have been made to understand the molecular basis of synovial sarcoma, but the origin tissue of synovial sarcoma is still not clarified. A SYT-SSX fusion gene, a product of chromosomal translocation t(X;18)(p11;q11), is a wellknown feature of synovial sarcoma and it is considered to play a critical role in the oncogenesis of synovial sarcoma (Turc-Carel et al., 1986; Clark et al., 1994; Brett et al., 1997; Lim et al., 1998; Soulez et al., 1999) . Furthermore, several groups reported the gene expression profile analysis using cDNA microarray and revealed that synovial sarcoma showed a distinct gene expression pattern compared with other spindle cell sarcomas (Nagayama et al., 2002; Nielsen et al., 2002; Segal et al., 2003) .
We previously analysed gene expression profiles of 47 soft tissue sarcomas using a genome-wide cDNA microarray consisting of 23 040 genes and found that Frizzled homologue 10 (FZD10) was upregulated specifically in synovial sarcomas at a very high level (Nagayama et al., 2002) . FZD10 is a member of the Frizzled family and considered as a seven-transmembrane Wnt-signaling receptor (Koike et al., 1999) . When FZD10 expression was suppressed using specific siRNAs, the growth of synovial sarcoma cells was significantly suppressed (Nagayama et al., 2005) , indicating an essential role of FZD10 in the growth or survival of the sarcoma cells. As FZD10 expression was absent or hardly detectable in any normal organs except the placenta, we considered that novel therapeutics targeting this molecule would be specifically effective to cancers and would have no or little risk for adverse reactions (Nagayama et al., 2005) .
In this study, we report further biological mechanisms of FZD10 overexpression in synovial sarcoma cells. Our data presented here indicate that FZD10 enhances phosphorylation of the Dishevelled 2 (Dvl2) and Dishevelled 3 (Dvl3) complex, and results in significant activation of the Rac1-JNK signaling pathway. As a result, it causes rearrangement of the actin cytoskeleton structure and the enhancement of anchorage-independent cell growth. These results suggest the critical involvement of FZD10 transactivation in development and progression of synovial sarcoma.
Results

Regulation of Dvl2 and Dvl3 by FZD10
FZD10 was previously reported to be involved in canonical WNT-b/catenin signaling in human airway smooth muscle cells (Wang et al., 2005) as well as in mouse development (Nunnally and Parr, 2004) . However, we found no activation of b-catenin/TCF (T-cell factor) signaling in synovial sarcoma cells in which FZD10 was expressed at a high level (data not shown), suggesting that FZD10 activation is not related to the canonical WNT signaling pathway in synovial sarcoma cells. Therefore, we considered a possibility that the downstream signaling of FZD10 in synovial sarcoma was different from the cases reported here. Dvl proteins are known to act as an important scaffold protein in the WNT-Frizzled signals (Wharton, 2003) . A large number of signaling proteins are suggested to bind to Dvl proteins, through which signals in the divergent pathways, such as cell motility, cell polarity and migration, are mediated through the non-canonical WNT signaling. Hence, we investigated possible correlations in the expression levels of the FZD10 protein and the Dvl members, and found some correlations between FZD10 expression and Dvl2 and Dvl3 expression levels in synovial sarcoma cell lines by western blot analysis, whereas no significant correlation was observed between FZD10 and Dvl1 (data not shown). Western blot analysis using anti-Dvl2 and anti-Dvl3 antibodies detected enhancement of a higher-molecular-weight band of Dvl2 protein (polyclonal antibody) as well as the total protein level of Dvl3 in 1273/99-FZD10 stableexpressing cell lines (FZD10-1 and FZD10-2) ( Figure 1a) . Moreover, interestingly when we used an anti-Dvl2 monoclonal antibody (MAb10B5), which is known not to recognize phosphorylated Dvl2 (Gonza´-lez-Sancho et al., 2004), we could not detect Dvl2 protein in FZD10-positive YaFuSS cells, but could detect Dvl2 after treatment of l-protein phosphatase (Supplementary Figure S1) . The result strongly implied that Dvl2 was highly phosphorylated in FZD10-positive cells.
Subsequently, to investigate a possible modification of Dvl3, we treated cellular extracts from the FZD10-2 cell line with l-protein phosphatase and found the disappearance of Dvl3 upper bands, indicating that the Dvl3 protein was also phosphorylated in FZD10-positive cells (Figure 1b) . Furthermore, disappearance of a nonphosphorylated form of Dvl2 and enhancement of a phosphorylated form of Dvl3 were observed in synovial sarcoma cell lines, SYO-1 and HS-SY-II, which showed a high level of endogenous FZD10 expression, whereas we found high levels of the non-phosphorylated forms of Dvl2 and Dvl3 in FZD10-negative cell lines, 1273/99 and LoVo (Figure 1c) .
Phosphorylation of the Dvl family protein has been reported and a large number of kinases were implicated to be involved (Hino et al., 2003; Kinoshita et al., 2003; Wharton, 2003; Bryja et al., 2007a) . To examine a kinase possibly involved in the FZD10-induced phosphorylation of Dvl2 and Dvl3, FZD10-positive cell lines were treated with various kinase inhibitors and effects on their phosphorylation levels were investigated. Among various kinase inhibitors, we found that D4476, which is known to be a specific inhibitor of Casein kinase 1 (CK1) (Rena et al., 2004; Bain et al., 2007) , was able to reduce the phosphorylation of Dvl2 and Dvl3 in FZD10-overexpressing SYO-1 cells, suggesting a possible involvement of CK1 in the phosphorylation of Dvl2 and Dvl3 in FZD10-positive cells (Figure 1d ).
Synergistic phosphorylation of Dvl2 and Dvl3 in the presence of FZD10 interested us in Dvl2/Dvl3 heterooligomerization (Rothba¨cher et al., 2000; Angers et al., 2006) . To investigate this possibility, we constructed the myc-tagged-Dvl2 vector (Dvl2-myc) and transfected into FZD10-stably expressing cells (FZD10-2) or Mock cells (Mock2). The results showed that Dvl2 and Dvl3 formed a complex, irrespective of the existence of FZD10 (Figure 1e ).
Disruption of actin cytoskeleton by FZD10 overexpression
As the Dvl family is known to be involved in the regulation of the actin cytoskeleton structure (Capelluto et al., 2002; Endo et al., 2005; Wechezak and Coan, 2005) , we examined actin fibers in cells with or without FZD10 expression by immunocytochemical analysis. The actin stress fiber was completely disassembled in HuBM-Bmi1-hT-immortalized mesenchymal stem cells transfected with FZD10 ( Figure 2a ; ii and iv) as well as in FZD10-introduced 1273/99 cells (Figure 2a ; vi and viii), whereas it was well assembled in their parental cells (Figure 2a; i, iii, v and vii) . Interestingly, we observed lamellipodia at the cell periphery in the FZD10-overexpressing cells (Figure 2a ; ii, iv, vi and viii), but not in the cells without the introduction of FZD10 plasmid (Figure 2a; i, iii, v and vii) . These findings indicate that overexpression of FZD10 led to the disruption of the actin stress fiber structure, possibly due to the regulation of Dvl proteins.
Subsequently, to examine an effect of FZD10 on RhoA activity, we transfected an FZD10-specific siRNA oligonucleotide into a synovial sarcoma cell line, SYO-1 cells, and performed a RhoA activation assay. Suppression of FZD10 expression resulted in a significant increase in RhoA activity as compared with the cells transfected with a control siEGFP (Figure 2b) . Furthermore, we observed actin cytoskeleton in HS-SY-II synovial sarcoma cells treated with FZD10 siRNA (Figure 2c ). These findings suggest that overexpression of FZD10 suppressed the RhoA activation, although the detailed mechanisms remain to be elucidated.
Enhancement of anchorage-independent cell growth by FZD10 through Rac1 and JNK activation Small GTPase protein Rac1 is known to be an essential signal-transduction molecule in actin organization (Ridley et al., 1992) and in the mediation of the noncanonical WNT signaling (Habas et al., 2003) . Moreover, c-Jun N-terminal , 2006) and functions as a mediator in the Rac1 signaling pathway (Coso et al., 1995; Minden et al., 1995; Rosso et al., 2005) . Hence, we investigated the effect of FZD10 on Rac1 and JNK pathways. Ectopic expression of HA-tagged FZD10 protein increased an active GTP-bound form of Rac1 in 1273/99 cells, whereas the total amount of Rac1 remained unchanged ( Figure 3a ). Conversely, knockdown of endogenous (Figure 3c ). On the other hand, we confirmed that knockdown of FZD10 by siRNA in SYO-1 cells resulted in the suppression of endogenous JNK activity (P-JNK), as compared with siEGFPtreated cells (Figure 3d ). These findings suggest that overexpression of FZD10 induced the activation of Rac1 and the phosphorylation of JNK. As the phosphorylation of Dvl proteins was regulated by FZD10 expression (Figure 1 ), Dvls are suspected to be mediators for the Rac1-JNK activation, directly or indirectly. Using siRNA, we showed that phosphorylation of endogenous JNK induced by FZD10 overexpression was completely inhibited in the cells in which either Dvl2 or Dvl3 was depleted, whereas the FZD10 level was unchanged in these cells (Figures 3e and f) . Taken together, these results strongly suggest that FZD10 overexpression induces Rac1 and JNK activation through phosphorylation of Dvl2 and Dvl3 proteins. Furthermore, as the Rac1 activation was indicated to be important for the inhibition of detachment-induced cell death (anoikis) (Frisch and Screaton, 2001; Cheng et al., 2004) , we investigated the effect of FZD10 on anchorage-independent cell growth. When the cells were cultured in soft agar, the numbers of colonies in 1273/99-FZD10-1 and 1273/99-FZD10-2 were increased up to two-fold in comparison with the parental 1273/99 cells or those transfected with mock control (Mock1) (Figure 3g ). Conversely, HS-SY-II cells transfected with FZD10 siRNA showed significant suppression of cell growth in soft agar, compared with the cells transfected with EGFP siRNA as a control (Figure 3h ). These results suggest that overexpression of FZD10 enhances anchorage-independent survival through activation of the Dvl2/3-Rac1-JNK pathway.
We also investigated primary synovial sarcoma tissues and found high levels of phosphorylation of Dvl2 and Dvl3 as well as enhancement of JNK phosphorylation by western blot (Figure 4a ). The level of phosphorylated JNK was correlated with the amount of FZD10 protein in immunohistochemical analyses (Figure 4b ). Taken together, overexpression of FZD10 is considered to cause activation of the Dvl-Rac1-JNK pathway in vivo as well as in vitro.
Discussion
We previously reported that FZD10, a member of the Frizzled family, was significantly transactivated in synovial sarcoma (Nagayama et al., 2002) , but little was known about the mechanism it utilized to transmit oncogenic signals in synovial sarcoma cells. We first examined the effect of FZD10 on nuclear b-catenin accumulation and Tcf/Lef reporter activity (the canonical signaling pathway), but found no activation of them by FZD10 expression (data not shown). Hence, we considered a possible involvement of FZD10 in the noncanonical signaling and demonstrated in this study that overexpression of FZD10 enhanced the anchorageindependent cell growth through the activation of the Rac1-JNK pathway as well as the destruction of the actin stress fiber structure caused by downregulation of the RhoA activity ( Figure 5 ). Furthermore, we showed the remarkable increase of phosphorylation of both Dvl2 and Dvl3 in the presence of FZD10. Among the diverse signal transduction pathways mediated by Dvls, regulation of small GTPase activity and following rearrangement of actin cytoskeleton is one of the most important cellular processes, including development, neurite retraction (Kishida et al., 2004) , cell motility, migration (Endo et al., 2005) , etc. As it has been reported that several kinases for the phosphorylation of the Dvl family are involved in response to ligand stimulation (Hino et al., 2003; Kinoshita et al., 2003; , we screened a possible candidate kinase(s) by treating a variety of kinase inhibitors, and found that the treatment of CK1-specific inhibitor, D4476, effectively suppressed the phosphorylation of Dvl2 and Dvl3. Involvement of CK1 in the Wnt-related signaling pathway has been implicated recently; CK1 enhances Wnt-3a-induced activation of the b-catenin signaling through Dvl-1 and Frat-1 binding (Hino et al., 2003) . In addition, CK1 inhibitor, D4476, blocked the differentiation of primary dopaminergic neuronal precursor cells (Bryja et al., 2007a) . Phosphorylated Dvl protein was reported to be involved in the full activation of b-catenin indicated by active b-catenin-specific antibody (Bryja et al., 2007b) . In our results, phosphorylated Dvl3 was pulled down with an active Rac1 in the presence of FZD10 (Supplementary Figure S2) . Therefore, it is suggested that Rac1-JNK activation under FZD10 overexpression requires phosphorylation of both Dvl2 and Dvl3 by CK1, although a further detailed mechanism has to be elucidated.
Rho GTPase family proteins are known to be the key regulators of actin cytoskeleton dynamics and to play critical roles in planar cell polarity/non-canonical WNTFrizzled cascade (Paterson et al., 1990; Hall, 1998; Wiggan and Hamel, 2002 Upregulation of JNK phosphorylation was observed in primary synovial sarcomas as well as in synovial sarcoma cell lines. The Rac1-JNK cascade was considered to be activated in the presence of FZD10, but this activation was blocked by the knockdown of either Dvl3 or Dvl2 as well as by the knockdown of FZD10 (Figure 3) . We also observed that Rac1 activation by FZD10 possibly induced lamellipodia formation and enhanced anchorage-independent growth. In addition, an active Cdc42 was also increased in FZD10-overexpressing HEK293 cells (Supplementary Figure S3) . Similarly to our findings, it was reported that Rho inactivation caused detachment from the substratum, and transformed the adherent fibroblasts and Vero cells into a round shape, indicating that Rho and Rac have opposing functions (Aepfelbacher et al., 1996) . Taken together, our findings suggest that FZD10 has a critical role in the highly metastatic feature of synovial sarcoma.
In conclusion, we have shown that FZD10 is involved in the development/progression of synovial sarcoma by regulating actin reorganization and anchorage-independent cell growth. Owing to the highly specific expression in tumor and the involvement in tumor progression, FZD10 is a promising molecular target to improve the prognosis of synovial sarcoma.
Materials and methods
Cells lines and tissue specimens
A colon cancer cell line LoVo was purchased from American Type Culture Collection (ATCC, Rockville, MD, USA). YaFuSS, derived from synovial sarcoma, and HuBM-Bmi1-hT, an immortalized mesenchymal stem cell line by transfection of Bmi and hTERT, were kindly provided by Professor Toguchida (Faculty of Medicine, Kyoto University, Japan). SYO-1 was a gift from Dr A Kawai (National Cancer Center, Japan), and 1273/99 from Dr O Larsson (Karolinska Institute, Sweden). All cells were cultured under their respective depositors' recommendation; that is, Ham's F-12 nutrient mixture (Invitrogen, Carlsbad, CA, USA) for LoVo and 1273/ 99 cell lines, Dulbecco's modified Eagle's medium (Invitrogen) for HEK293, SYO-1, HS-SY-II, and HuBM-Bmi1-hT cell lines. All cell lines were grown in monolayers in media supplemented with 10% fetal bovine serum and 1% antibiotic/ antimycotic solution, and maintained at 37 1C in air containing 5% CO 2 . Primary synovial sarcoma samples were obtained with written informed consent, and snap-frozen in liquid nitrogen immediately after resection and stored at À80 1C. The use of these tissue samples was approved by the IRBs (Faculty of Medicine, Kyoto University and Institute of Medical Science, The University of Tokyo). Each tumor sample was fixed in 10% formalin and routinely processed for hematoxylin and eosin staining to establish a pathological diagnosis by Dr J Toguchida.
Semiquantitative RT-PCR Total RNAs were extracted from each of the cell lines and primary tumor samples using TRIzol reagent (Invitrogen). The extracted RNAs were treated for 30 min at room temperature with 30 units of DNase I (Roche, Basel, Switzerland) in the presence of 1 unit of RNase inhibitor (TOYOBO, Osaka, Japan). After inactivation at 70 1C for 10 min, 3 mg each of RNA were reversely transcribed for single-stranded cDNAs using oligo (dT)12-18 primer and Superscript II (Invitrogen) at 42 1C for 60 min. We prepared appropriate dilutions of each single-stranded cDNA for subsequent PCR by monitoring b-actin as a quantitative control. PCR amplification was performed using EX-taq polymerase (TAKARA BIO, Ohtsu, Japan) and the cDNAs as templates with the following primers: 5 0 -TATCGGGCTCTTCTCTGTGC-3 0 and 5 0 -GA CTGGGCAGGGATCTCATA-3 0 for FZD10; and 5 0 -CATCC ACGAAACTACCTTCAACT-3 0 and 5 0 -TCTCCTTAGAGA GAAGTGGGGTG-3 0 for b-actin. PCRs were optimized for the number of cycles to ensure product intensity within the logarithmic phase of amplification. The PCR conditions were 95 1C for 30 s, 58 1C for 30 s and 72 1C for 30 s for 21 cycles for b-actin and 28 cycles for FZD10. The PCR products were resolved by electrophoresis on 2.0% agarose gels, and their band intensities were quantified using NIH Image analysis software (http://rsb.info.nih.gov/nih-image/).
Western blot analysis
Cells and primary tumor samples were lysed with a lysis buffer (50 mM Tris-HCl, 0.5% Igepal, 0.5% Triton X-100, 2% glycerol, 150 mM NaCl, 1 mM NaF, 1 mM sodium orthovanadate, pH 7.4) including 0.2% protease inhibitor cocktail III (Calbiochem, San Diego, CA, USA). After homogenization, the cell lysates were incubated on ice for 30 min and centrifuged at 14 000 r.p.m. for 15 min to separate the supernatant from the cell debris. The amount of total protein was estimated by a protein assay kit (Bio-Rad, Hercules, CA, USA), and then the cell lysates were mixed with SDS sample buffer and boiled for 3 minutes before loading into SDS-polyacrylamide gels (Bio-Rad). After electrophoresis, the proteins were blotted onto a nitrocellulose membrane (GE Healthcare, Buckinghamshire, UK). After blocking with 4% BlockAce blocking solution (Dainippon Pharmaceutical Co. Ltd, Osaka, Japan), the membranes were incubated with the primary antibodies. Finally, membrane was incubated with horseradish peroxide-conjugated secondary antibody (1:10 000 dilution; GE Healthcare), and proteins were visualized by the ECL detection reagent (GE Healthcare). bActin was used as a loading control. The primary antibodies used are as follows: b-Actin (1:30 000 dilution; clone AC-15, SigmaAldrich, St Louis, MO, USA), DVL2 (1:500 dilution; Dvl-2 H-75 or 10B5, Santa Cruz Biotechnology, Santa Cruz, CA, USA), DVL3 (1:500 dilution; Dvl-3 4D3, Santa Cruz Biotechnology), HA (1:3000 dilution; anti-HA high affinity, clone 3F10; Roche), c-Myc (1:1000 dilution; 9E10, Santa Cruz Biotechnology), JNK (1:500 dilution; SAPK/JNK, Cell Signaling Technology, Danvers, MA, USA), phosphorylated JNK (1:500 dilution; Phospho-SAPK/JNK Thr183/Tyr185, Cell Signaling Technology), RhoA (1:500 dilution; Santa Cruz Biotechnology), Rac1 (1:1000 dilution; anti-Rac1 monoclonal antibody, B&D Transduction, Lexington, KY, USA) and Cdc42 mouse monoclonal IgG3 (1:1000 dilution; Santa Cruz Biotechnology).
l-Protein phosphatase assay Cells were lysed with a lysis buffer (50 mM Tris-HCl, 0.5% Igepal, 0.5% Triton X-100, 2% glycerol, 150 mM NaCl, 0.2% protease inhibitor cocktail Set III (Calbiochem), pH 7.4). Aliquots of 10 mg protein were supplemented with 2 mM MnCl 2 , incubated with 800 units of l-protein phosphatase (New England Biolabs, Beverly, MA, USA) or 25 mM of sodium fluoride for 60 min at 30 1C. Incubation was terminated by the addition of SDS sample buffer and the samples FZD10 signaling in synovial sarcoma cells C Fukukawa et al were boiled for 3 min, subjected to western blot analysis according to the method described in the above section.
Plasmid constructs
To construct the plasmid designed to express a full-length FZD10 with HA-epitope tag at its N-terminus protein, we inserted an HA-tag sequence at the downstream of the signal peptide sequence (1-22 residues of FZD10) because FZD10 is a cytoplasmic membrane protein. Firstly, we generated a signal peptide sequence fragment of FZD10 protein (1-22 residues) by PCR, using PrimeSTAR HS DNA polymerase (TAKARA BIO) with the following set of primers: 5 0 -AAGTCGACGC CAGCATGCAGCGCCCG-3 0 and 5 0 -AACTCGAGGCT GATGGCGGCGCACGAG-3 0 (underline indicates restriction enzyme sites). The PCR product was digested with SalI and XhoI, and ligated into the XhoI site of pCAGGS/neovector (pCAGGS/neo signal). Secondly, to generate the HA epitope tag, a following set of oligonucleotides, 5 0 -GCATGTCGAC TACCCATACGATGTTCCAGATTACGCTCTCGAGGCA T-3 0 and 5 0 -ATGCCTCGAGAGCGTAATCTGGAACA TCGTATGGGTAGTCGACATGC-3 0 (underline indicates restriction enzyme sites) was mixed, and denatured at 94 1C for 3 min and gradually cooled down to 37 1C (0.1 1C/s slope) for annealing. The annealed fragment was digested with SalI and XhoI, and ligated into the XhoI site of pCAGGS/ neo signal (pCAGGS/neo signal HA). Thirdly, to amplify the cDNA fragment consisting of residues 23-581 of FZD10, we performed PCR using the following primers: 5 0 -AA GTCGACTCCATGGACATGGAGCGCCC-3 0 and 5 0 -AA CTCGAGTCACACGCAGGTGGGCGACT-3 0 (underline indicates restriction enzyme sites). The PCR fragment of FZD10 (23-581) was digested with SalI and XhoI and ligated into the XhoI site of pCAGGS/neo signal HA vector (pCAGGS/neo HA FZD10).
To construct the Dvl2 expression vector, the entire coding sequence of Dvl2 was amplified by PCR using the following primers: 5 0 -AAGGTACCATGGCGGGTAGCAGCAC-3 0 and 5 0 -AAGGATCCCATAACATCCACAAAGAACTCGC-3 0 (underline indicates restriction enzyme sites). The PCR fragment was digested with KpnI and BamHI, and ligated into pcDNA 3.1/myc-His (Invitrogen). DNA sequences of all constructs were confirmed by DNA sequencing (ABI3700, PE Applied Biosystems, Foster, CA, USA).
We used siRNA oligonucleotides (Sigma-Aldrich Japan KK, Tokyo, Japan) to further verify the knockdown effects of FZD10, Dvl2 and Dvl3 on signaling pathways. The sequences targeting each gene were as follows: 5 0 -GAAGCAGCACGA CUUCUUC-3 0 (sense) and 5 0 -GAAGAAGUCGUGCUGCU UC-3 0 (antisense) for siEGFP (control); 5 0 -GCCGUAG GUUAAAGAAGAA-3 0 (sense) and 5 0 -UUCUUCUUUAAC CUACGGC-3 0 (antisense) for siFZD10; 5 0 -GAUUACC AUCCCUAAUGCU-3 0 (sense) and 5 0 -AGCAUUAGGGA UGGUAAUC-3 0 (antisense) for siDvl3; and 5 0 -GCAAGU GGGACUAGCGAUG-3 0 (sense) and 5 0 -CAUCGCUA GUCCCACUUGC (antisense) for siDvl2.
Cell transfection and treatments HEK293, COS-7 and HuBM-Bmi1-hT cells were transfected with expression vector constructs as described above using FuGENE 6 transfection reagent (Roche). SYO-1 and HS-SY-II cells were transfected with siRNA oligonucleotides using Lipofectamine RNAiMAX reagent (Invitrogen) according to the manufacturer's protocol. For the establishment of cell lines that stably overexpress FZD10, HA-tagged FZD10 expression vector (pCAGGS/neo HA FZD10) or mock vector (pCAGGS/ neo) was transfected into 1273/99 synovial sarcoma cells, in which a undetectable level of FZD10 expression was observed, using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. Transfected cells were incubated in the culture medium containing 0.2 mg/ml of neomycin (geneticin; Invitrogen). Three weeks later, 20 individual colonies were selected by limiting dilution and screened for HA-FZD10 stably overexpressing clones. The expression level of HA-FZD10 in each clone was examined by western blot and immunocytochemical staining analyses using an anti-HA monoclonal antibody (Roche). We established two independent clones with FZD10 overexpression and designated them as 1273/99-FZD10-1 and 1273/99-FZD10-2. Two independent cell lines transfected with mock vector were designated as Mock1 and Mock2. Treatment of SYO-1 cells with D4476 was performed as follows: 10 ml of 10 mM D4476 was diluted in a mixture of 100 ml serum-free medium and 3 ml of FuGENE 6 transfection reagent (Roche) at room temperature before adding this solution to the cultured cells.
Immunocytochemical and immunohistochemical staining analyses
For immunocytochemical analysis, cells were plated onto a COL I-coated cover glass (IWAKI, Tokyo, Japan) placed in a six-well plate at a density of 5 Â 10 4 cells/well. Subsequently, the cells were fixed with phosphate-buffered saline (SigmaAldrich) containing 4% paraformaldehyde for 15 min at room temperature, and then permeabilized with 0.1% Triton X-100 for 2 min at room temperature, followed by incubation with an anti-HA monoclonal antibody (Roche). Bound antibody was detected using goat anti-rat IgG (H þ L) conjugated with Alexa Fluor 488 (1:1000 dilution; Molecular Probe, Eugene, OR, USA). Actin cytoskeleton was stained using phalloidin conjugated with Alexa Fluor 594 (1:40 dilutions; Molecular Probe).
For immunohistochemical analysis, sections of 4-mm-thick paraffin-embedded normal adult human tissues (lung, heart, liver, kidney, colon and placenta) (BioChain, Hayward, CA, USA) and clinical synovial sarcoma specimens were deparaffinized and processed for antigen retrieval in Target Retrieval Solution (pH 9) (DAKO Cytomation, Carpinteria, CA, USA) at 125 1C for 30 s. After treatment with serum-free protein blocking (DAKO Cytomation) for 30 min, slides were incubated with 10 mg/ml of mouse anti-FZD10 monoclonal antibody 92-13 (Fukukawa et al., 2008) and 1:50 dilution of phospho-SAPK/JNK (Thr183/Tyr185) antibody (Cell Signaling Technology). Bound antibodies were detected using Alexa Fluor 488 goat anti-mouse IgG (H þ L) and Alexa Fluor 594 goat anti-rabbit IgG (H þ L) (Molecular Probe). Fluorescent images were obtained with a TCS SP2 AOBS microscope (Leica, Tokyo, Japan).
RhoA and Rac1 activation assays Activated forms of RhoA and Rac1 were detected using the RhoA assay reagent (Rhotekin PBD, agarose conjugate; Upstate Biotechnology, Lake Placid, NY, USA) and the Rac/cdc42 assay reagent (PAK-1 PBD, agarose conjugate; Upstate biotechnology), respectively, according to the manufacturer's instructions. For RhoA assay, SYO-1 cells were transfected with siRNA oligonucleotides against either FZD10 or EGFP as a control. The cells were cultured for 72 h after transfection and subjected to the assay. For Rac1 and cdc42 assays, 1273/99 or HEK293 cells were transfected with pCAGGS-HA-FZD10 vector or pCAGGS mock vector. In addition, HS-SY-II cells were also transfected with siRNA oligonucleotides against either FZD10 or EGFP as a control. Subsequently, for both assays, the cells were lysed in an MLB FZD10 signaling in synovial sarcoma cells C Fukukawa et al buffer (25 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH 7.5, 150 mM NaCl, 0.5% Igepal, 10% glycerol, 10 mM MgCl 2 , 1mM EDTA, 25 mM NaF, 1 mM sodium orthovanadate and 0.1% protease inhibitor cocktail III). Appropriate amounts of RhoA assay or Rac/cdc42 assay reagent were mixed with the lysates and incubated at 4 1C for 60 min. The conjugates were washed three times with the MLB buffer and subjected to western blot analysis according to the method described in the western blot analysis section.
Anchorage-independent growth assay Anchorage-independent growth was examined by colony formation assay in soft agar. A cell suspension consisting of 1 Â 10 4 viable 1273/99 cells (stably overexpressing HA-FZD10, cells transfacted with a mock vector or parent cells) or HS-SY-II cells, transfected with siRNA oligonucleotides against either FZD10 or EGFP in appropriate media containing 0.3% agar, was plated onto a 3-ml base layer of 0.5% agar with the same media composition. Cultures were allowed to grow for 3 weeks, and colonies were stained with 4 mg/ml of iodonitrotetrazolium chloride.
Immunoprecipitation 1273/99 stably FZD10-expressing clone (FZD10-2) or Mock control (Mock2) were transfected with either pcDNA 3.1/mycHis-Dvl2 or an empty vector using FuGENE6 transfection reagent (Roche). Transfected cells were lysed with the lysis buffer described above. The cell lysates were incubated with anti-c-myc antibody (9E10) and protein G-sepharose (SigmaAldrich). Bound proteins were washed five times with the lysis buffer and eluted with the SDS sample buffer. Eluted proteins were analysed by SDS-polyacrylamide gel electrophoresis and western blot analysis.
Statistical analysis
Data points for the anchorage-independent growth assay represent the means along with 95% confidence intervals (CIs) of two independent experiments. Student's t-test was applied for comparisons of colony numbers in anchorage-independent growth assays. All statistical tests were two-sided, and P-values o0.05 were considered to be statistically significant.
